Eiger to Participate in Piper Jaffray Healthcare Conference
PALO ALTO, Calif., Nov. 19, 2018 /PRNewswire/ --Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference on November 27 at 4:00 PM ET at Lotte NY Palace Hotel in New York City.
A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
Eiger will also host one-on-one meetings with investors.
About Eiger Eiger is a late-stage biopharmaceutical company focused on the accelerated development and commercialization of a pipeline of targeted therapies for rare and ultra-rare diseases. Our lead program is advancing Lonafarnib into a Phase 3, single pivotal trial to treat Hepatitis Delta Virus (HDV) Infection, initiating in 2018. Eiger is preparing an NDA for Lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) with plans to file in 2019. For additional information about Eiger, please visit www.eigerbio.com.
Investors: Ingrid Choong, PhD Email: [email protected] Phone: 1-650-619-6115
Owlstone Medical ("Owlstone"), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has secured funding from the Bill & Melinda Gates Foundation ("the Gates Foundation" or "the...
Straine Dental Management (SDM), a dentist-owned, dentist-led dental services organization (DSO), continues its national expansion with a strategic affiliation with Jolly Family Dental ? North Little Rock, Arkansas. SDM's entry into its 13th state...
Onconic Therapeutics, a leading biotechnology company in Korea, today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD) in...
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.
To access the call by phone, please go to this registration link and you...
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...
